Research
How to read an FDA drug label
A prescribing label is the one document that exists only for a compound with an actual FDA approval behind it. It follows a required structure, the same sections appear in the same order on every one, and reading three of them tells you more than any marketing page will.
Why this document is different from everything else on this site
Most of what this site sources — briefing documents, warning letters, bulk-substance nomination entries, registered trials — describes compounds that do not have this document at all, because they have never been approved. A prescribing label, sometimes called a package insert, exists only for a drug that went through full FDA review and came out the other side approved.
That makes it the highest-value single document available for the small number of compounds this site grades strong evidence. It is also the document readers are least likely to have actually opened, because it is written for prescribers rather than a consumer audience and it runs to dozens of pages.
The structure is not the manufacturer's choice. Federal regulation requires prescribing information to follow a specific content and format, known as the Physician Labeling Rule, so that the same categories of information appear in the same order on every approved drug's label. Once the structure is familiar, any label can be navigated the same way.
The Highlights section is a table of contents with teeth
Every label opens with a section literally titled Highlights of Prescribing Information. It states plainly that it does not include everything needed to use the drug safely and effectively. It is a summary, with a pointer to the full text for each item.
Immediately below that heading, if the drug carries one, sits the boxed warning: FDA's strongest warning category, printed first, in a bordered box, before the drug's own indication is even stated. On Wegovy's label, that is exactly the order: the boxed warning for thyroid C-cell tumors appears before the Indications and Usage section that says what the drug is for.
That ordering is a signal in itself. A label written for a drug FDA considers to carry no risk grave enough for this treatment would have no boxed warning at all. A label that opens with one is telling a reader, before anything else, what the regulator considered serious enough to put first.
Indications and Usage says exactly who the drug is for, and exactly who it is not for
This section states the approved use in precise, bounded language, not a general description. Wegovy's label indicates it as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. That covers adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related condition.
The word adjunct is doing real work in that sentence. The approval is for use alongside diet and physical activity changes, not as a replacement for them. That qualifier is part of the approved indication, not a piece of general advice layered on top of it.
This section also states Limitations of Use — conditions the drug has not been studied for or should not be combined with. Wegovy's label states it should not be used with other semaglutide-containing products or another GLP-1 receptor agonist, and that it has not been studied in patients with a history of pancreatitis. A limitation of use is not a footnote. It marks the edge of what the approval actually covers.
Contraindications and Warnings and Precautions answer two different questions
Contraindications lists situations where the drug must not be used at all — an absolute line, not a judgment call. Wegovy's label contraindicates it in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It also contraindicates it in anyone with known hypersensitivity to semaglutide or the product's other ingredients.
Warnings and Precautions is longer and covers risks that call for judgment, monitoring or caution rather than an outright bar. On the same label, this section covers acute pancreatitis, acute gallbladder disease, and hypoglycemia risk in combination with certain other medications. It goes on to cover acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, increased heart rate, and suicidal behavior or ideation.
Reading only the Highlights version of this section is reading a bullet list of headings. The full prescribing information behind each numbered cross-reference explains what was actually observed and in what setting, which is where the real content sits.
Adverse Reactions describes what happened in the trials, at a stated threshold
This section is a report of what was measured during the drug's clinical trials, with a stated frequency cutoff. Wegovy's label lists the reactions reported in five percent or more of trial participants: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia and dizziness. The list continues with abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis and gastroesophageal reflux disease.
A frequency threshold matters because it tells a reader what the list includes and excludes. A five-percent cutoff means this is the common-reaction list, not an exhaustive one, and the full prescribing information behind it typically breaks reactions down by dose and by trial.
This section is descriptive reporting, not a risk ranking or a recommendation. It states what trial participants experienced under studied conditions; it does not predict any individual reader's experience.
Clinical Studies is where the trial evidence itself lives
Further into the full prescribing information, a Clinical Studies section describes the trials that supported approval: their design, their population, and their results, in more numeric detail than the Highlights summary carries. This is the section that connects the label back to the published trial literature.
For a drug like Wegovy, this is where a reader would find the trial-level detail behind the approval, cross-referenced to the same trial program described in this site's own article on the compound's evidence.
Reading this section against a published trial paper is a useful check in either direction. The label states what FDA reviewed and accepted. The published paper carries detail the label summarizes rather than reproduces in full.
What a label cannot tell you
A label describes the approved product exactly as reviewed. It says nothing about a compounded version of the same molecule, which has not been through the same review and carries no label of its own in the same regulatory sense.
A label also does not update itself the moment new information appears. Labels are revised through a formal supplement process, and a reader checking one should note the revision date printed on it rather than assume it reflects the newest available safety information.
None of this is guidance for using any drug. It is a map for reading a document that already exists, written by the one authority with full access to the data behind it.
Key takeaways
- A prescribing label exists only for a drug with an actual FDA approval — most compounds on this site have none.
- Federal regulation (the Physician Labeling Rule) requires every label to follow the same section order, which is why one label teaches you to read any other.
- A boxed warning, when present, is printed before the drug's own indication — its presence or absence is itself informative.
- Contraindications are an absolute bar; Warnings and Precautions cover risks requiring judgment or monitoring — the two sections answer different questions.
- Adverse Reactions reports what trials measured at a stated frequency threshold, not a complete or predictive risk list.
- A label describes the approved product exactly as reviewed; it does not extend to a compounded version of the same molecule.
Frequently asked questions
What is the difference between a drug label and a package insert?
They refer to the same document in ordinary usage: the prescribing information FDA approves alongside a drug. "Label" is the regulatory term; "package insert" describes how it is physically distributed with the product. Both mean the full prescribing information, not just the Highlights summary at the front.
Why do labels all follow the same structure?
Because federal regulation requires it. The Physician Labeling Rule, codified at 21 CFR 201.56 and 201.57, sets the required content and format for prescription drug labeling. Its specific purpose is to make the same categories of information appear in the same order across different drugs. That structure is why a reader who learns to navigate one label can navigate any of them.
Does every approved drug have a boxed warning?
No. A boxed warning appears only when FDA has identified a risk serious enough to warrant its strongest label category, printed first and bordered. Its absence on a given label means FDA did not require one for that drug. Its presence, as on Wegovy's label for thyroid C-cell tumors, means FDA required the drug's most serious identified risk to be the first thing a prescriber reads.
Can I use a drug label to judge a compounded version of the same molecule?
Not directly. A label describes the approved product exactly as FDA reviewed it: a specific formulation, made by a specific manufacturer, tested in specific trials. A compounded preparation using the same active ingredient has not gone through that review and does not carry that label's assurance, whatever ingredient list the two share.
Where can I find a drug's current label?
FDA's Drugs@FDA database holds the current and historical labeling for approved drugs, searchable by drug name or application number. A label found there carries a printed approval or revision date. That date is worth checking against the date a source citing it was written, since labels are updated through a formal supplement process and an older labeling document may not reflect the newest version.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Wegovy (semaglutide) injection — prescribing information — U.S. Food and Drug Administration, June 2021
- Labeling for Human Prescription Drug and Biological Products — Implementing the PLR Content and Format Requirements — U.S. Food and Drug Administration, February 2013
- 21 CFR 201.57 — Specific requirements on content and format of labeling for human prescription drug and biological products — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026